Screening, diagnosis, and management of patients with Fabry disease

• Verfasst von: Schiffmann, Raphael [VerfasserIn]
• Verfasst von: Ries, Markus [VerfasserIn]
• Titel: Screening, diagnosis, and management of patients with Fabry disease
• Titelzusatz: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
• Verf.angabe: Raphael Schiffmann, Derralynn A. Hughes, Gabor E. Linthorst, Alberto Ortiz, Einar Svarstad, David G. Warnock, Michael L. West and Christoph Wanner for Conference participants
• Jahr: 2017
• Jahr des Originals: 2016
• Umfang: 10 S.
• Fussnoten: Other Conference participants Daniel G. Bichet, Canada; Erik Ilsø Christensen, Denmark; Ricardo Correa-Rotter, Mexico; Perry M. Elliott, UK; Sandro Feriozzi, Italy; Agnes B. Fogo, USA; Dominique P. Germain, France; Carla E.M. Hollak, Netherlands; Robert J. Hopkin, USA; Jack Johnson, USA; Ilkka Kantola, Finland; Jeffrey B. Kopp, USA; Jürgen Kröner, Germany; Ales Linhart, Czech Republic; Ana Maria Martins, Brazil; Dietrich Matern, USA; Atul B. Mehta, UK; Renzo Mignani, Italy; Behzad Najafian, USA; Ichiei Narita, Japan; Kathy Nicholls, Australia; Greg T. Obrador, Mexico; João Paulo Oliveira, Portugal; Antonio Pisani, Italy; Juan Politei, Argentina; Uma Ramaswami, UK; Markus Ries, Germany; Wim Terryn, Belgium; Camilla Tøndel, Norway; Roser Torra, Spain; Bojan Vujkovac, Slovenia; Stephen Waldek, UK; Jerry Walter, USA ; Available online 18 December 2016 ; Gesehen am 17.04.2019
• Titel Quelle: Enthalten in: Kidney international
• Ort Quelle: New York, NY : Elsevier, 1972
• Jahr Quelle: 2017
• Band/Heft Quelle: 91(2017), 2, Seite 284-293
• ISSN Quelle: 1523-1755
• DOI: doi:10.1016/j.kint.2016.10.004
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: chronic kidney disease
• Sach-SW: enzyme replacement therapy
• Sach-SW: Fabry disease
• Sach-SW: Fabry nephropathy
• Sach-SW: standard of care
• K10plus-PPN: 1663395713

Abstract

Patients with Fabry disease (FD) are at a high risk for developing chronic kidney disease and cardiovascular disease. The availability of specific but costly therapy has elevated the profile of this rare condition. This KDIGO conference addressed controversial areas in the diagnosis, screening, and management of FD, and included enzyme replacement therapy and nonspecific standard-of-care therapy for the various manifestations of FD. Despite marked advances in patient care and improved overall outlook, there is a need to better understand the pathogenesis of this glycosphingolipidosis and to determine the appropriate age to initiate therapy in all types of patients. The need to develop more effective specific therapies was also emphasized.